SA News • Jun. 29, 2010
There are no Focus articles on SVYSY.
There are no Transcripts on SVYSY.
Jun. 29, 2010, 7:45 AMAbbott Laboratories (ABT) is looking to sell the flu-vaccine business it picked up in its 2009 purchase of Solvay's (SVYSY.PK) pharmaceutical unit. A sale could be worth as much as €500M ($619M), and potential bidders include such heavyweights as GlaxoSmithKline (GSK) and AstraZeneca (AZN). | Comment!
Sep. 27, 2009, 9:48 AMAbbott (ABT) is close to announcing a deal to buy Belgian conglomerate Solvay's (SVYSY.PK) drug unit for about $7.6B in cash. A deal could be announced as early as Monday. Abbott and Solvay already sell two drugs for cholesterol and triglycerides together; a deal would give Abbott access to Solvay's drugs for hypertension and Parkinson's disease. (WSJ) | Comment!
There are no StockTalks on this stock yet.
Currently, there's no company description for SVYSY.
Country: United States
Other News & PR